HAT-SIL-TG-1&AT

HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5 under hypoxic conditions[1].

Product Specifications

CAS Number

[2973282-50-5]

UNSPSC

12352005

Target

JAK; STAT

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hat-sil-tg-1-at.html

Solubility

10 mM in DMSO

Smiles

CC1=CC(COC(N2C=C(C(C3=NC4=C(N3)C=CC(CN5CCOCC5)=C4)=N2)NC(NC6CC6)=O)=O)=C(C(COC(N7CCN(CC7)C8=CC=C(C=C8)NC9=NC=C(C(NC%10=CC(S(=O)(NC(C)(C)C)=O)=CC=C%10)=N9)C)=O)=C1)OCC%11=CN=C(N%11C)[N+]([O-])=O

Molecular Formula

C60H69N17O11S

Molecular Weight

1236.36

References & Citations

[1]Chen X, et al. A JAK tyrosine kinase and pseudokinase Co-inhibition strategy combines enhanced potency and on-demand activation. Eur J Med Chem. 2023 Mar 15;250:115198.